Objective
Neurodegeneration associated with Parkinson’s (PD) and Alzheimer’s (AD) diseases begins several years prior to the appearance of clinical symptoms and in total, over eight million people in Europe were living with PD or AD in year 2010. Currently, there are no diagnostic tools which allow for early diagnose and/or monitoring the progression these diseases in living patients and the available therapeutic methods only offer transient symptomatic relief. Increasing evidence suggest that early diagnosis and intervention are crucial for any future therapeutic strategies to treat and/or slow the progression of these devastating diseases.
The target of the PoC project is to establish the innovation potential of using the antibodies developed by the PI as diagnostic tools in PD and AD. To fulfill this target, testing and commercialization activities will take place. Specifically, the PoC project will focus on the in-vitro and in-vivo testing of the antibodies using the blood and the cerebrospinal fluid obtained post-mortem from PD and AD patients as well as from animal transgenic models. If successful, these novel antibodies would enable the development of preclinical diagnostic tools for detecting and measuring protein aggregation and other biomarkers, which could ultimately lead to the development of novel and desperately needed pre-diagnostic and therapeutic strategies for treating and/or preventing neurodegeneration in PD and AD. With the help of the PI’s research team, the Technology Transfer Office of EPFL and subcontractors, the PI will develop a commercialization roadmap required to establish proof of concept.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences neurobiology
- medical and health sciences basic medicine neurology dementia alzheimer
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine neurology parkinson
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
ERC-2012-PoC
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Host institution
1015 LAUSANNE
Switzerland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.